✦ LIBER ✦

Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukaemias in vitro and in vivo

✍ Scribed by J. Golay; N. Di Gaetano; D. Amico; E. Cittera; A. M. Barbui; R. Giavazzi; A. Biondi; A. Rambaldi; M. Introna

Book ID: 108672989
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 257 KB
Volume: 128
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2004.05322.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

In vitro experimental211At-anti-CD33 ant

In vitro experimental211At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin

✍ Thorsten Petrich; Zekiye Korkmaz; Doris Krull; Cornelia Frömke; Geerd J. Meyer; 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 223 KB

Methotrexate and aminopterin exhibit sim

Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma

✍ Min H. Kang; Narine Harutyunyan; Connor P. Hall; Rachael A. Papa; Richard B. Loc 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 241 KB

Chimeric, divalent and tetravalent anti-

Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines

✍ Xiao-Yun Liu; Laurentiu M. Pop; Lydia Tsai; Iliodora V. Pop; Ellen S. Vitetta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 295 KB

## Abstract CD19 is an attractive therapeutic target for treating human B‐cell tumors. In our study, chimeric (c) divalent (cHD37) and tetravalent (cHD37‐DcVV) anti‐CD19 monoclonal antibodies (MAbs) were constructed, expressed and evaluated for their binding to human 19‐positive (CD19^+^) tumor cel